View in EDS

Bexmarilimab-induced macrophage activation leads to treatment benefit in solid tumors: The phase I/II first-in-human MATINS trial.

Saved in:
Bibliographic Details
Title: Bexmarilimab-induced macrophage activation leads to treatment benefit in solid tumors: The phase I/II first-in-human MATINS trial.
Authors: Rannikko JH; MediCity Research Laboratory and InFLAMES Flagship, University of Turku, Turku, Finland; Turku Doctoral Program of Molecular Medicine, University of Turku, Turku, Finland., Verlingue L; Institut Gustave Roussy, Paris and Centre Leon Berard in Lyon, Lyon, France., de Miguel M; START-CIOCC HM Sanchinarro, Madrid, Spain., Pasanen A; Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland., Robbrecht D; Erasmus Medical Center/Cancer Institute, Rotterdam, the Netherlands., Skytta T; Tampere University Hospital, Tampere, Finland., Iivanainen S; Oulu University Hospital, University of Oulu, Oulu, Finland., Shetty S; University of Birmingham/University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK., Ma YT; University of Birmingham/University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK., Graham DM; The Christie NHS Foundation Trust, Manchester, UK., Arora SP; Mays Cancer Center, UT Health San Antonio, San Antonio, TX, USA., Jaakkola P; Department of Oncology, Turku University Hospital and University of Turku, Turku, Finland., Yap C; Clinical Trials and Statistics Unit, The Institute of Cancer Research, London, UK., Xiang Y; INDIVIDRUG Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland., Mandelin J; Faron Pharmaceuticals Ltd, Turku, Finland., Karvonen MK; Faron Pharmaceuticals Ltd, Turku, Finland., Jalkanen J; Faron Pharmaceuticals Ltd, Turku, Finland., Karaman S; INDIVIDRUG Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland; Wihuri Research Institute, Helsinki, Finland., Koivunen JP; Oulu University Hospital, University of Oulu, Oulu, Finland; Faron Pharmaceuticals Ltd, Turku, Finland., Minchom A; Drug Development Unit, Royal Marsden Hospital/Institute of Cancer Research, Sutton, UK., Hollmén M; MediCity Research Laboratory and InFLAMES Flagship, University of Turku, Turku, Finland; Faron Pharmaceuticals Ltd, Turku, Finland. Electronic address: maijal@utu.fi., Bono P; Terveystalo Finland and University of Helsinki, Helsinki, Finland. Electronic address: petri.bono@terveystalo.com.
Source: Cell reports. Medicine [Cell Rep Med] 2023 Dec 19; Vol. 4 (12), pp. 101307. Date of Electronic Publication: 2023 Dec 05.
Publication Type: Clinical Trial, Phase II; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Cell Press Country of Publication: United States NLM ID: 101766894 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2666-3791 (Electronic) Linking ISSN: 26663791 NLM ISO Abbreviation: Cell Rep Med Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 38056464
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Bexmarilimab-induced macrophage activation leads to treatment benefit in solid tumors: The phase I/II first-in-human MATINS trial.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Rannikko+JH%22">Rannikko JH</searchLink>; MediCity Research Laboratory and InFLAMES Flagship, University of Turku, Turku, Finland; Turku Doctoral Program of Molecular Medicine, University of Turku, Turku, Finland.<br /><searchLink fieldCode="AU" term="%22Verlingue+L%22">Verlingue L</searchLink>; Institut Gustave Roussy, Paris and Centre Leon Berard in Lyon, Lyon, France.<br /><searchLink fieldCode="AU" term="%22de+Miguel+M%22">de Miguel M</searchLink>; START-CIOCC HM Sanchinarro, Madrid, Spain.<br /><searchLink fieldCode="AU" term="%22Pasanen+A%22">Pasanen A</searchLink>; Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland.<br /><searchLink fieldCode="AU" term="%22Robbrecht+D%22">Robbrecht D</searchLink>; Erasmus Medical Center/Cancer Institute, Rotterdam, the Netherlands.<br /><searchLink fieldCode="AU" term="%22Skytta+T%22">Skytta T</searchLink>; Tampere University Hospital, Tampere, Finland.<br /><searchLink fieldCode="AU" term="%22Iivanainen+S%22">Iivanainen S</searchLink>; Oulu University Hospital, University of Oulu, Oulu, Finland.<br /><searchLink fieldCode="AU" term="%22Shetty+S%22">Shetty S</searchLink>; University of Birmingham/University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.<br /><searchLink fieldCode="AU" term="%22Ma+YT%22">Ma YT</searchLink>; University of Birmingham/University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.<br /><searchLink fieldCode="AU" term="%22Graham+DM%22">Graham DM</searchLink>; The Christie NHS Foundation Trust, Manchester, UK.<br /><searchLink fieldCode="AU" term="%22Arora+SP%22">Arora SP</searchLink>; Mays Cancer Center, UT Health San Antonio, San Antonio, TX, USA.<br /><searchLink fieldCode="AU" term="%22Jaakkola+P%22">Jaakkola P</searchLink>; Department of Oncology, Turku University Hospital and University of Turku, Turku, Finland.<br /><searchLink fieldCode="AU" term="%22Yap+C%22">Yap C</searchLink>; Clinical Trials and Statistics Unit, The Institute of Cancer Research, London, UK.<br /><searchLink fieldCode="AU" term="%22Xiang+Y%22">Xiang Y</searchLink>; INDIVIDRUG Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.<br /><searchLink fieldCode="AU" term="%22Mandelin+J%22">Mandelin J</searchLink>; Faron Pharmaceuticals Ltd, Turku, Finland.<br /><searchLink fieldCode="AU" term="%22Karvonen+MK%22">Karvonen MK</searchLink>; Faron Pharmaceuticals Ltd, Turku, Finland.<br /><searchLink fieldCode="AU" term="%22Jalkanen+J%22">Jalkanen J</searchLink>; Faron Pharmaceuticals Ltd, Turku, Finland.<br /><searchLink fieldCode="AU" term="%22Karaman+S%22">Karaman S</searchLink>; INDIVIDRUG Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland; Wihuri Research Institute, Helsinki, Finland.<br /><searchLink fieldCode="AU" term="%22Koivunen+JP%22">Koivunen JP</searchLink>; Oulu University Hospital, University of Oulu, Oulu, Finland; Faron Pharmaceuticals Ltd, Turku, Finland.<br /><searchLink fieldCode="AU" term="%22Minchom+A%22">Minchom A</searchLink>; Drug Development Unit, Royal Marsden Hospital/Institute of Cancer Research, Sutton, UK.<br /><searchLink fieldCode="AU" term="%22Hollmén+M%22">Hollmén M</searchLink>; MediCity Research Laboratory and InFLAMES Flagship, University of Turku, Turku, Finland; Faron Pharmaceuticals Ltd, Turku, Finland. Electronic address: maijal@utu.fi.<br /><searchLink fieldCode="AU" term="%22Bono+P%22">Bono P</searchLink>; Terveystalo Finland and University of Helsinki, Helsinki, Finland. Electronic address: petri.bono@terveystalo.com.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101766894%22">Cell reports. Medicine</searchLink> [Cell Rep Med] 2023 Dec 19; Vol. 4 (12), pp. 101307. <i>Date of Electronic Publication: </i>2023 Dec 05.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Clinical Trial, Phase II; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Cell+Press%22">Cell Press </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101766894 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2666-3791 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2226663791%22">26663791 </searchLink><i>NLM ISO Abbreviation: </i>Cell Rep Med <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=38056464
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/j.xcrm.2023.101307
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 101307
    Titles:
      – TitleFull: Bexmarilimab-induced macrophage activation leads to treatment benefit in solid tumors: The phase I/II first-in-human MATINS trial.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Rannikko JH
      – PersonEntity:
          Name:
            NameFull: Verlingue L
      – PersonEntity:
          Name:
            NameFull: de Miguel M
      – PersonEntity:
          Name:
            NameFull: Pasanen A
      – PersonEntity:
          Name:
            NameFull: Robbrecht D
      – PersonEntity:
          Name:
            NameFull: Skytta T
      – PersonEntity:
          Name:
            NameFull: Iivanainen S
      – PersonEntity:
          Name:
            NameFull: Shetty S
      – PersonEntity:
          Name:
            NameFull: Ma YT
      – PersonEntity:
          Name:
            NameFull: Graham DM
      – PersonEntity:
          Name:
            NameFull: Arora SP
      – PersonEntity:
          Name:
            NameFull: Jaakkola P
      – PersonEntity:
          Name:
            NameFull: Yap C
      – PersonEntity:
          Name:
            NameFull: Xiang Y
      – PersonEntity:
          Name:
            NameFull: Mandelin J
      – PersonEntity:
          Name:
            NameFull: Karvonen MK
      – PersonEntity:
          Name:
            NameFull: Jalkanen J
      – PersonEntity:
          Name:
            NameFull: Karaman S
      – PersonEntity:
          Name:
            NameFull: Koivunen JP
      – PersonEntity:
          Name:
            NameFull: Minchom A
      – PersonEntity:
          Name:
            NameFull: Hollmén M
      – PersonEntity:
          Name:
            NameFull: Bono P
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 19
              M: 12
              Text: 2023 Dec 19
              Type: published
              Y: 2023
          Identifiers:
            – Type: issn-electronic
              Value: 2666-3791
          Numbering:
            – Type: volume
              Value: 4
            – Type: issue
              Value: 12
          Titles:
            – TitleFull: Cell reports. Medicine
              Type: main
ResultId 1